Innate Pharma Stock Forecast - 20 Period Moving Average

IPHA Stock  USD 2.06  0.28  15.73%   
The 20 Period Moving Average forecasted value of Innate Pharma on the next trading day is expected to be 1.93 with a mean absolute deviation of 0.12 and the sum of the absolute errors of 4.76. Innate Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Innate Pharma stock prices and determine the direction of Innate Pharma's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Innate Pharma's historical fundamentals, such as revenue growth or operating cash flow patterns.
  
At present, Innate Pharma's Payables Turnover is projected to increase slightly based on the last few years of reporting. The current year's Receivables Turnover is expected to grow to 1.30, whereas Inventory Turnover is projected to grow to (28.2 K). . As of November 6, 2024, Common Stock Shares Outstanding is expected to decline to about 53.1 M. The current year's Net Loss is expected to grow to about (49.7 M).
A commonly used 20-period moving average forecast model for Innate Pharma is based on a synthetically constructed Innate Pharmadaily price series in which the value for a trading day is replaced by the mean of that value and the values for 20 of preceding and succeeding time periods. This model is best suited for price series data that changes over time.

Innate Pharma 20 Period Moving Average Price Forecast For the 7th of November

Given 90 days horizon, the 20 Period Moving Average forecasted value of Innate Pharma on the next trading day is expected to be 1.93 with a mean absolute deviation of 0.12, mean absolute percentage error of 0.02, and the sum of the absolute errors of 4.76.
Please note that although there have been many attempts to predict Innate Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Innate Pharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).

Innate Pharma Stock Forecast Pattern

Backtest Innate PharmaInnate Pharma Price PredictionBuy or Sell Advice 

Innate Pharma Forecasted Value

In the context of forecasting Innate Pharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Innate Pharma's downside and upside margins for the forecasting period are 0.02 and 5.48, respectively. We have considered Innate Pharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Market Value
2.06
1.93
Expected Value
5.48
Upside

Model Predictive Factors

The below table displays some essential indicators generated by the model showing the 20 Period Moving Average forecasting method's relative quality and the estimations of the prediction error of Innate Pharma stock data series using in forecasting. Note that when a statistical model is used to represent Innate Pharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.
AICAkaike Information Criteria77.369
BiasArithmetic mean of the errors 0.102
MADMean absolute deviation0.1161
MAPEMean absolute percentage error0.0589
SAESum of the absolute errors4.759
The eieght-period moving average method has an advantage over other forecasting models in that it does smooth out peaks and valleys in a set of daily observations. Innate Pharma 20-period moving average forecast can only be used reliably to predict one or two periods into the future.

Predictive Modules for Innate Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Innate Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.091.785.34
Details
Intrinsic
Valuation
LowRealHigh
0.163.186.74
Details
5 Analysts
Consensus
LowTargetHigh
6.877.558.38
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Innate Pharma. Your research has to be compared to or analyzed against Innate Pharma's peers to derive any actionable benefits. When done correctly, Innate Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Innate Pharma.

Other Forecasting Options for Innate Pharma

For every potential investor in Innate, whether a beginner or expert, Innate Pharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Innate Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Innate. Basic forecasting techniques help filter out the noise by identifying Innate Pharma's price trends.

Innate Pharma Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Innate Pharma stock to make a market-neutral strategy. Peer analysis of Innate Pharma could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics with similar companies.
 Risk & Return  Correlation

Innate Pharma Technical and Predictive Analytics

The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Innate Pharma's price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Innate Pharma's current price.

Innate Pharma Market Strength Events

Market strength indicators help investors to evaluate how Innate Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Innate Pharma shares will generate the highest return on investment. By undertsting and applying Innate Pharma stock market strength indicators, traders can identify Innate Pharma entry and exit signals to maximize returns.

Innate Pharma Risk Indicators

The analysis of Innate Pharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Innate Pharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting innate stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:
Check out Historical Fundamental Analysis of Innate Pharma to cross-verify your projections.
For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.75)
Earnings Share
(0.44)
Revenue Per Share
0.419
Quarterly Revenue Growth
(0.69)
Return On Assets
(0.14)
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.